Editas Medicine pricing shares at $16 for year's first IPO: reports

Editas Medicine Inc. EDIT, +0.00% priced shares for its initial public offering at the low end of the range, according to media reports late Tuesday, for what will be 2016’s first IPO. Editas will price 5.9 million shares at $16 a share, at the low end of its $16 to $18 range, to raise $94.4 million. That give Editas a market valuation of $571 million, according to Reuters. Cambridge, Mass.-based Editas develops treatments for genetic-based diseases via editing gene sequences.

Most Recent Posts:

Doctor showing a patient information on a touchscreen device

The Medically Engineered Solutions in Healthcare (MESH) Incubator: A case study of innovation “push”

In an opinion piece for STAT, Marc Succi, MD, Clinician-in-Residence at Mass General Brigham Innovation, addresses the…

Read More
WMIF 2022 Recap

2022 World Medical Innovation Forum | Day 3 Recap

The final day of the World Medical Innovation Forum began with a discussion on the fast-moving landscape…

Read More
WMIF 2022 Recap

2022 World Medical Innovation Forum | Day 2 Recap

Day 2 of World Medical Innovation Forum kicked off with a fireside chat with FDA commissioner Robert…

Read More